关注
Mathieu Bolhuis
Mathieu Bolhuis
University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands
在 umcg.nl 的电子邮件经过验证
标题
引用次数
引用次数
年份
Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB
S De Lorenzo, JW Alffenaar, G Sotgiu, R Centis, L D'Ambrosio, S Tiberi, ...
European Respiratory Journal 41 (6), 1386-1392, 2013
2092013
Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC–MS/MS
DH Vu, RA Koster, MS Bolhuis, B Greijdanus, RV Altena, DH Nguyen, ...
Talanta 121, 9-17, 2014
1032014
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
MS Bolhuis, R van Altena, D van Soolingen, WCM de Lange, DRA Uges, ...
European Respiratory Journal 42 (6), 1614-1621, 2013
1022013
Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis
DH Vu, MS Bolhuis, RA Koster, B Greijdanus, WCM De Lange, ...
Antimicrobial agents and chemotherapy 56 (11), 5758-5763, 2012
992012
Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis
MA Zuur, MS Bolhuis, R Anthony, A den Hertog, T van der Laan, B Wilffert, ...
Expert opinion on drug metabolism & toxicology 12 (5), 509-521, 2016
892016
Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics
S Ghimire, MS Bolhuis, MGG Sturkenboom, OW Akkerman, ...
European Respiratory Journal 47 (6), 1867-1869, 2016
842016
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams
MS Bolhuis, PN Panday, AD Pranger, JGW Kosterink, JWC Alffenaar
Pharmaceutics 3 (4), 865-913, 2011
80*2011
Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment
MS Bolhuis, OW Akkerman, MGG Sturkenboom, S Ghimire, S Srivastava, ...
Clinical Infectious Diseases 67 (suppl_3), S327-S335, 2018
792018
Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis
OW Akkerman, OFF Odish, MS Bolhuis, WCM de Lange, HPH Kremer, ...
Clinical Infectious Diseases 62 (4), 523-524, 2016
682016
End TB with precision treatment!
EPM van der Burgt, MGG Sturkenboom, MS Bolhuis, OW Akkerman, ...
European Respiratory Journal 47 (2), 680-682, 2016
612016
Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study
MS Bolhuis, S Tiberi, G Sotgiu, S De Lorenzo, JGW Kosterink, ...
European Respiratory Journal 46 (4), 1205-1207, 2015
542015
Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring
SHJ van den Elsen, LM Oostenbrink, SK Heysell, D Hira, DJ Touw, ...
Therapeutic drug monitoring 40 (1), 17-37, 2018
502018
Clarithromycin significantly increases linezolid serum concentrations
MS Bolhuis, R van Altena, DRA Uges, TS van der Werf, JGW Kosterink, ...
Antimicrobial agents and chemotherapy 54 (12), 5418-5419, 2010
502010
Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation
J Millard, H Pertinez, L Bonnett, EM Hodel, V Dartois, JL Johnson, ...
Journal of Antimicrobial Chemotherapy 73 (7), 1755-1762, 2018
472018
Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis
J Kamp, MS Bolhuis, S Tiberi, OW Akkerman, R Centis, WC de Lange, ...
International journal of antimicrobial agents 49 (6), 688-694, 2017
452017
Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry
JWC Alffenaar, M Bolhuis, K Van Hateren, M Sturkenboom, O Akkerman, ...
Antimicrobial agents and chemotherapy 59 (9), 5675-5680, 2015
392015
Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis
MS Bolhuis, R Van Altena, K Van Hateren, WCM de Lange, B Greijdanus, ...
Antimicrobial agents and chemotherapy 57 (8), 3676-3680, 2013
382013
In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin
JA Dijkstra, T Van der Laan, OW Akkerman, MS Bolhuis, WCM de Lange, ...
Antimicrobial agents and chemotherapy 62 (3), 10.1128/aac. 01724-17, 2018
362018
Amikacin dosing for MDR tuberculosis: a systematic review to establish or revise the current recommended dose for tuberculosis treatment
MGG Sturkenboom, N Simbar, OW Akkerman, S Ghimire, MS Bolhuis, ...
Clinical Infectious Diseases 67 (suppl_3), S303-S307, 2018
332018
Clinical standards for drug-susceptible pulmonary TB
OW Akkerman, R Duarte, S Tiberi, HS Schaaf, C Lange, JWC Alffenaar, ...
The International Journal of Tuberculosis and Lung Disease 26 (7), 592-604, 2022
312022
系统目前无法执行此操作,请稍后再试。
文章 1–20